Posted by Michael Wonder on 18 Jan 2023
Medunik Canada obtains new Notice of Compliance from Health Canada for Ruzurgi (amifampridine) following a favourable Canadian Federal Court of Appeal ruling
17 January 2023 - Medunik Canada is pleased to announce that on 9 January 2023, the Federal Court of Appeal of Canada set aside an earlier decision of its Trial Division which had removed a Notice of Compliance on Medunik’s Ruzurgi (amifampridine) for Lambert-Eaton Myasthenic syndrome patients and sent the matter back to Health Canada.
The Notice of Compliance which had been previously granted by Health Canada is now restored.
